Viewing Study NCT06607458

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:21 AM
Ignite Modification Date: 2026-04-13 @ 5:19 PM
Study NCT ID: NCT06607458
Status: RECRUITING
Last Update Posted: 2025-11-07
First Post: 2024-09-14
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
Sponsor: Delcath Systems Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Refractory Metastatic Colorectal Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None melphalan/HDS View
None melphalan/hepatic delivery system View
None trifluridine-tipiracil View
None trifluridine-tipiracil (FTD-TPI) View
None trifluridine-tipiracil (FTD-TPI) plus bevacizumab View
None trifluridine-tipiracil plus bevacizumab View
None hepatic delivery system View
None melphalan View
None liver dominant disease View
None colorectal cancer View
None metastatic colorectal cancer View
None refractory metastatic colorectal cancer View
None rectal cancer View